Sage Therapeutics Inc (NASDAQ:SAGE) shares, rose in value on Friday, March 28, with the stock price down by -4.39% to the previous day’s close as strong demand from buyers drove the stock to $8.28.
Actively observing the price movement in the last trading, the stock closed the session at $8.66, falling within a range of $8.24 and $8.81. The value of beta (5-year monthly) was 0.82. Referring to stock’s 52-week performance, its high was $19.34, and the low was $4.62. On the whole, SAGE has fluctuated by 15.16% over the past month.
With the market capitalization of Sage Therapeutics Inc currently standing at about $509.06 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-10.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that SAGE’s technical picture suggests that short-term indicators denote the stock is a 100% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of SAGE currently trading nearly 5.20% and 10.80% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.19, while the 7-day volatility ratio is showing 4.30% which for the 30-day chart, stands at 4.09%. Furthermore, Sage Therapeutics Inc (SAGE)’s beta value is 0.45, and its average true range (ATR) is 0.32.
A comparison of Sage Therapeutics Inc (SAGE) with its peers suggests the former has fared considerably weaker in the market. SAGE showed an intraday change of -4.39% in last session, and over the past year, it shrunk by -55.53%%.
Data on historical trading for Sage Therapeutics Inc (NASDAQ:SAGE) indicates that the trading volumes over the past 10 days have averaged 1.05 and over the past 3 months, they’ve averaged 1.87 million. According to company’s latest data on outstanding shares, there are 61.36 million shares outstanding.
Nearly 11.95% of Sage Therapeutics Inc’s shares belong to company insiders and institutional investors own 74.82% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 4.26 million shares as on 2025-03-14, resulting in a short ratio of 2.86. According to the data, the short interest in Sage Therapeutics Inc (SAGE) stood at 785.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 4.41 million. The stock has risen by 52.49% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SAGE stock heading into the next quarter.
